The abstract is read at the publisher; the summary is JClub's.
In mouse and human cDC1s, CARM1 is a selective negative regulator of cancer antigen cross-presentation, and its inhibition enhances cDC1-mediated T cell priming.
- Why it matters: Improving intratumoral cDC1 cross-presentation is a key gap in therapeutic strategies for strengthening the cancer-immunity cycle.
- What they did: The study used Carm1 gene inactivation and a CARM1 inhibitor, assessing cDC1 versus cDC2 antigen presentation, tumor cDC1 activation/accumulation, and T cell priming with a cancer neoantigen vaccine.
- The result: CARM1 inhibition increased chromatin accessibility at BATF3-Jun and RelA sites and promoted intratumoral cDC1 function without altering cDC1 homeostasis, supporting CARM1 as a therapeutic target.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.